Effectiveness and Usefulness of Bone Turnover Marker in Osteoporosis Patients: A Multicenter Study in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: This study aimed to investigate real-world data of C-terminal telopeptide (CTX), propeptide of type I collagen (P1NP), and osteocalcin through present multicenter clinical study, and retrospectively analyze the usefulness of bone turnover markers (BTMs) in Koreans. Methods: The study focused on pre- and post-menopausal patients diagnosed with osteoporosis and excluded patients without certain test results or with test intervals of over 1 year. The demographic data and 3 BTMs (CTX, P1NP, and osteocalcin) were collected. The patients were classified by demographic characteristics and the BTM concentrations were analyzed by the group. Results: Among women with no history of fractures, the levels of P1NP (N=2,100) were 43.544±36.902, CTX (N=1,855) were 0.373±0.927, and osteocalcin (N=219) were 10.81 ±20.631. Among men with no history of fractures, the levels of P1NP (N=221) were 48.498±52.892, CTX (N=201) were 0.370±0.351, and osteocalcin (N=15) were 7.868 ±10.674. Treatment with teriparatide increased the P1NP levels after 3 months in both men and women, with a 50% increase observed in women. Similarly, treatment with denosumab decreased the CTX levels after 3 months in both men and women, with a reduction of 50% observed in women. Conclusions: The results of this study can contribute to the accurate assessment of bone replacement status in Koreans. We also provide the P1NP level in the Korean population for future comparative studies with other populations.
Abstract
Background: This study aimed to investigate real-world data of C-terminal telopeptide (CTX), propeptide of type I collagen (P1NP), and osteocalcin through present multicenter clinical study, and retrospectively analyze the usefulness of bone turnover markers (BTMs) in Koreans. Methods: The study focused on pre- and post-menopausal patients diagnosed with osteoporosis and excluded patients without certain test results or with test intervals of over 1 year. The demographic data and 3 BTMs (CTX, P1NP, and osteocalcin) were collected. The patients were classified by demographic characteristics and the BTM concentrations were analyzed by the group. Results: Among women with no history of fractures, the levels of P1NP (N=2,100) were 43.544±36.902, CTX (N=1,855) were 0.373±0.927, and osteocalcin (N=219) were 10.81 ±20.631. Among men with no history of fractures, the levels of P1NP (N=221) were 48.498±52.892, CTX (N=201) were 0.370±0.351, and osteocalcin (N=15) were 7.868 ±10.674. Treatment with teriparatide increased the P1NP levels after 3 months in both men and women, with a 50% increase observed in women. Similarly, treatment with denosumab decreased the CTX levels after 3 months in both men and women, with a reduction of 50% observed in women. Conclusions: The results of this study can contribute to the accurate assessment of bone replacement status in Koreans. We also provide the P1NP level in the Korean population for future comparative studies with other populations.
참고문헌 (19)
- Vasikaran S, "Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment : A need for international reference standards", Osteoporos Int, 22, pp.391~420 (2011)[DOI]
- Szulc P, "Biochemical markers of bone turnover : Potential use in the investigation and management of postmenopausal osteoporosis", Osteoporos Int, 19, pp.1683~1704 (2008)[DOI]
- 박소영, "Clinical Application of Bone Turnover Markers in Osteoporosis in Korea", 대한골대사학회지, 26(1), pp.19~24 (2019), 대한골대사학회
- 조동혁, "Reference Intervals for Bone Turnover Markers in Korean Healthy Women", 대한골대사학회지, 27(1), pp.43~52 (2020), 대한골대사학회
- 유준일, "Age-related Reference Intervals for Total Collagen-I-N-terminal Propeptide in Healthy Korean Population", 대한골대사학회지, 25(4), pp.235~241 (2018), 대한골대사학회
- World Health Organization, "Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group", World Health Organ Tech Rep Ser, 843, pp.1~129 (1994)
- Greenblatt MB, "Bone turnover markers in the diagnosis and monitoring of metabolic bone disease", Clin Chem, 63, pp.464~474 (2017)[DOI]
- Bauer DC, "Biochemical markers of bone turnover, hip bone loss, and fracture in older men: The MrOS study", J Bone Miner Res, 24, pp.2032~2038 (2009)[DOI]
- Finnes TE, "Procollagen type 1 amino-terminal propeptide (P1NP) and risk of hip fractures in elderly Norwegian men and women. A NOREPOS study", Bone, 64, pp.1~7 (2014)[DOI]
- Reginster JY, "Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk", Bone, 34, pp.344~351 (2004)[DOI]
- Garnero P, "Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis", Clin Chem, 54, pp.188~196 (2008)[DOI]
- de Papp AE, "A cross-sectional study of bone turnover markers in healthy premenopausal women", Bone, 40, pp.1222~1230 (2007)[DOI]
- Glover SJ, "Rapid and robust response of biochemical markers of bone formation to teriparatide therapy", Bone, 45, pp.1053~1058 (2009)[DOI]
- Claudon A, "New automated multiplex assay for bone turnover markers in osteoporosis", Clin Chem, 54, pp.1554~1563 (2008)[DOI]
- 박소영, "Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment", 대한골대사학회지, 26(4), pp.213~224 (2019), 대한골대사학회
- Szulc P, "Biochemical markers of bone turnover in men", Calcif Tissue Int, 69, pp.229~234 (2001)[DOI]
- Adami S, "Determinants of bone turnover markers in healthy premenopausal women", Calcif Tissue Int, 82, pp.341~347 (2008)[DOI]
- Glover SJ, "Establishing a reference range for bone turnover markers in young, healthy women", Bone, 42, pp.623~630 (2008)[DOI]
- Rogers A, "A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy", Bone, 45, pp.1044~1052 (2009)[DOI]